Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Verapamil | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Verapamil | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Verapamil | hsa00071 | Fatty acid degradation | 2.52E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Verapamil | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Verapamil | hsa00310 | Lysine degradation | 4.57E-02 | 2 | Q96KQ7, Q02809 | EHMT2, PLOD1 | More | | Verapamil | hsa00500 | Starch and sucrose metabolism | 4.90E-05 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Verapamil | hsa00562 | Inositol phosphate metabolism | 2.00E-02 | 4 | P27987, P19174, P42338, Q02252 | ITPKB, PLCG1, PIK3CB, ALDH6A1 | More | | Verapamil | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Verapamil | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Verapamil | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | Verapamil | hsa00630 | Glyoxylate and dicarboxylate metabolism | 8.61E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | | Verapamil | hsa00730 | Thiamine metabolism | 1.21E-05 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | Verapamil | hsa00760 | Nicotinate and nicotinamide metabolism | 3.52E-02 | 1 | P21589 | NT5E | More | | Verapamil | hsa00770 | Pantothenate and CoA biosynthesis | 2.27E-02 | 2 | O95498, O95497 | VNN2, VNN1 | More | | Verapamil | hsa00970 | Aminoacyl-tRNA biosynthesis | 8.35E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Verapamil | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Verapamil | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Verapamil | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Verapamil | hsa01100 | Metabolic pathways | 3.52E-02 | 23 | P05089, O95455, P21953, P32320, P11766, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, Q08477, P15907, Q9UNP4, P37837, P32321, Q9BPW9, Q9UHY7, P43490, P46976, P06737 | ARG1, TGDS, BCKDHB, CDA, ADH5, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, CYP4F3, ST6GAL1, ST3GAL5, TALDO1, DCTD, DHRS9, ENOPH1, PBEF1, GYG1, PYGL | More | | Verapamil | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Verapamil | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Verapamil | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Verapamil | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Verapamil | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | Verapamil | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | | Verapamil | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Verapamil | hsa03040 | Spliceosome | 1.62E-02 | 8 | Q14562, O43143, O60508, P08579, Q07955, Q01130, Q13243, P11142 | DHX8, DHX15, CDC40, SNRPB2, SFRS1, SFRS2, SFRS5, HSPA8 | More | | Verapamil | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Verapamil | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Verapamil | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Verapamil | hsa04012 | ErbB signaling pathway | 2.00E-02 | 4 | P16333, P17252, P19174, P42338 | NCK1, PRKCA, PLCG1, PIK3CB | More | | Verapamil | hsa04014 | Ras signaling pathway | 7.71E-04 | 10 | P42338, P20827, P49767, Q13009, P17252, P14921, P0DP23, P62873, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, PRKCA, ETS1, CALM1, GNB1, GNG10, PLCG1 | More | | Verapamil | hsa04015 | Rap1 signaling pathway | 9.88E-03 | 8 | P20827, P49767, P11215, Q13009, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, ITGAM, TIAM1, PIK3CB, CALM1, PRKCA, PLCG1 | More | | Verapamil | hsa04020 | Calcium signaling pathway | 4.34E-02 | 6 | P27987, P17252, O15399, P19174, P0DP23, P49767 | ITPKB, PRKCA, GRIN2D, PLCG1, CALM1, VEGFC | More | | Verapamil | hsa04024 | cAMP signaling pathway | 4.34E-02 | 6 | P42338, P0DP23, Q13370, O15399, P25963, Q13009 | PIK3CB, CALM1, PDE3B, GRIN2D, NFKBIA, TIAM1 | More | | Verapamil | hsa04060 | Cytokine-cytokine receptor interaction | 4.71E-02 | 2 | P78552, O75509 | IL13RA1, TNFRSF21 | More | | Verapamil | hsa04062 | Chemokine signaling pathway | 1.25E-02 | 9 | P42338, P19174, P62873, P50151, P43250, Q13009, P14598, P42224, P25963 | PIK3CB, PLCG1, GNB1, GNG10, GRK6, TIAM1, NCF1, STAT1, NFKBIA | More | | Verapamil | hsa04070 | Phosphatidylinositol signaling system | 3.29E-03 | 6 | P19174, P0DP23, P42338, P23743, P27987, P17252 | PLCG1, CALM1, PIK3CB, DGKA, ITPKB, PRKCA | More | | Verapamil | hsa04071 | Sphingolipid signaling pathway | 6.08E-04 | 5 | P21453, Q9H228, P01375, Q13362, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | | Verapamil | hsa04072 | Phospholipase D signaling pathway | 9.70E-03 | 2 | Q92529, Q14344 | SHC3, GNA13 | More | | Verapamil | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Verapamil | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | Verapamil | hsa04150 | mTOR signaling pathway | 2.23E-02 | 3 | P42338, Q13322, P49841 | PIK3CB, GRB10, GSK3B | More | | Verapamil | hsa04151 | PI3K-Akt signaling pathway | 1.43E-02 | 12 | P42338, P20827, P49767, P08238, P62873, P50151, P16144, O15335, Q13751, P14784, P01568, P17252 | PIK3CB, EFNA1, VEGFC, HSP90AB1, GNB1, GNG10, ITGB4, CHAD, LAMB3, IL2RB, IFNA21, PRKCA | More | | Verapamil | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Verapamil | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Verapamil | hsa04217 | Necroptosis | 1.85E-04 | 12 | P01568, Q13489, P42224, P07900, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q13557, O43633 | IFNA21, BIRC3, STAT1, HSP90AA1, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, CAMK2D, CHMP2A | More | | Verapamil | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Verapamil | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Verapamil | hsa04360 | Axon guidance | 2.13E-03 | 7 | P16333, P20827, O95631, P17252, P42338, P23528, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, CFL1, PLCG1 | More | | Verapamil | hsa04370 | VEGF signaling pathway | 7.68E-03 | 3 | P19174, P42338, P17252 | PLCG1, PIK3CB, PRKCA | More | | Verapamil | hsa04380 | Osteoclast differentiation | 4.80E-02 | 4 | P06239, P42338, P14778, Q8N149 | LCK, PIK3CB, IL1R1, LILRA2 | More | | Verapamil | hsa04510 | Focal adhesion | 7.77E-03 | 9 | P16144, O75369, P42338, Q15942, P17252, O15335, Q13751, Q13489, P49767 | ITGB4, FLNB, PIK3CB, ZYX, PRKCA, CHAD, LAMB3, BIRC3, VEGFC | More | | Verapamil | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Verapamil | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | | Verapamil | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Verapamil | hsa04613 | Neutrophil extracellular trap formation | 2.15E-05 | 11 | P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Verapamil | hsa04621 | NOD-like receptor signaling pathway | 1.93E-02 | 8 | Q16539, P10599, Q9H1Y0, P43490, O00463, P01375, P09341, P12838 | MAPK14, TXN, ATG5, PBEF1, TRAF5, TNF, CXCL1, DEFA4 | More | | Verapamil | hsa04623 | Cytosolic DNA-sensing pathway | 4.57E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Verapamil | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | Verapamil | hsa04657 | IL-17 signaling pathway | 8.03E-06 | 10 | P07900, O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Verapamil | hsa04659 | Th17 cell differentiation | 5.33E-03 | 9 | P25963, P19174, P06239, P42224, P14784, P14778, P40189, P08238, P07766 | NFKBIA, PLCG1, LCK, STAT1, IL2RB, IL1R1, IL6ST, HSP90AB1, CD3E | More | | Verapamil | hsa04662 | B cell receptor signaling pathway | 7.25E-03 | 4 | P49841, P42338, P21854, Q8N149 | GSK3B, PIK3CB, CD72, LILRA2 | More | | Verapamil | hsa04664 | Fc epsilon RI signaling pathway | 2.00E-02 | 4 | P42338, P17252, P19174, P09917 | PIK3CB, PRKCA, PLCG1, ALOX5 | More | | Verapamil | hsa04666 | Fc gamma R-mediated phagocytosis | 8.08E-03 | 5 | P42338, P19174, P23528, P14598, P17252 | PIK3CB, PLCG1, CFL1, NCF1, PRKCA | More | | Verapamil | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Verapamil | hsa04713 | Circadian entrainment | 1.24E-02 | 5 | O15399, P0DP23, P17252, P62873, P50151 | GRIN2D, CALM1, PRKCA, GNB1, GNG10 | More | | Verapamil | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Verapamil | hsa04724 | Glutamatergic synapse | 8.08E-03 | 5 | O15399, P17252, P62873, P50151, P15104 | GRIN2D, PRKCA, GNB1, GNG10, GLUL | More | | Verapamil | hsa04725 | Cholinergic synapse | 4.26E-02 | 4 | P17252, P62873, P50151, P42338 | PRKCA, GNB1, GNG10, PIK3CB | More | | Verapamil | hsa04726 | Serotonergic synapse | 2.54E-02 | 5 | P17252, P62873, P50151, P33260, P09917 | PRKCA, GNB1, GNG10, CYP2C18, ALOX5 | More | | Verapamil | hsa04727 | GABAergic synapse | 1.23E-02 | 4 | P62873, P50151, P15104, P17252 | GNB1, GNG10, GLUL, PRKCA | More | | Verapamil | hsa04730 | Long-term depression | 3.52E-02 | 1 | Q14344 | GNA13 | More | | Verapamil | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Verapamil | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Verapamil | hsa04744 | Phototransduction | 1.67E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Verapamil | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.72E-02 | 3 | P14778, P42338, P24723 | IL1R1, PIK3CB, PRKCH | More | | Verapamil | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Verapamil | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Verapamil | hsa04914 | Progesterone-mediated oocyte maturation | 1.24E-02 | 5 | P42338, Q13370, Q9UJX4, P30304, P08238 | PIK3CB, PDE3B, ANAPC5, CDC25A, HSP90AB1 | More | | Verapamil | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Verapamil | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Verapamil | hsa04926 | Relaxin signaling pathway | 1.10E-03 | 10 | P25963, P42338, P62873, P50151, P18848, P22694, P49767, P14780, P17252, P30679 | NFKBIA, PIK3CB, GNB1, GNG10, ATF4, PRKACB, VEGFC, MMP9, PRKCA, GNA15 | More | | Verapamil | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Verapamil | hsa04929 | GnRH secretion | 3.63E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | Verapamil | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Verapamil | hsa04932 | Non-alcoholic fatty liver disease | 9.01E-04 | 7 | P49841, P18848, P01584, P13073, O15239, Q16718, O14521 | GSK3B, ATF4, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | | Verapamil | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.43E-02 | 5 | P42224, P42338, P49767, P17252, P19174 | STAT1, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Verapamil | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.38E-02 | 1 | P48048 | KCNJ1 | More | | Verapamil | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | Verapamil | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Verapamil | hsa04973 | Carbohydrate digestion and absorption | 4.12E-03 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Verapamil | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Verapamil | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | Verapamil | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | | Verapamil | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | | Verapamil | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | | Verapamil | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Verapamil | hsa05032 | Morphine addiction | 1.24E-02 | 5 | P62873, P50151, Q13370, P17252, P43250 | GNB1, GNG10, PDE3B, PRKCA, GRK6 | More | | Verapamil | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Verapamil | hsa05110 | Vibrio cholerae infection | 3.15E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | Verapamil | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.27E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Verapamil | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | Verapamil | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | | Verapamil | hsa05140 | Leishmaniasis | 2.47E-02 | 5 | P13612, O75015, P01375, P49006, Q16539 | ITGA4, FCGR3B, TNF, MARCKSL1, MAPK14 | More | | Verapamil | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Verapamil | hsa05145 | Toxoplasmosis | 3.45E-02 | 6 | P25963, Q13489, P42224, P09917, Q13751, P11142 | NFKBIA, BIRC3, STAT1, ALOX5, LAMB3, HSPA8 | More | | Verapamil | hsa05146 | Amoebiasis | 3.03E-03 | 8 | P09341, P19875, P14778, P27930, P01375, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, ARG1, GNA15, PRKACB | More | | Verapamil | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | Verapamil | hsa05163 | Human cytomegalovirus infection | 1.60E-03 | 14 | P42338, P01375, P25963, P62873, P50151, P0DP23, P49841, P14778, P17252, P25025, Q16539, O00463, P30101, P01568 | PIK3CB, TNF, NFKBIA, GNB1, GNG10, CALM1, GSK3B, IL1R1, PRKCA, CXCR2, MAPK14, TRAF5, PDIA3, IFNA21 | More | | Verapamil | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.56E-03 | 9 | P01568, P42224, P25963, P42338, P40189, P62873, P50151, P19174, P0DP23 | IFNA21, STAT1, NFKBIA, PIK3CB, IL6ST, GNB1, GNG10, PLCG1, CALM1 | More | | Verapamil | hsa05168 | Herpes simplex virus 1 infection | 6.31E-03 | 13 | P25963, P01568, P42224, Q07955, Q01130, Q13243, Q13489, P30101, P42338, Q13398, Q03923, O75820, Q9UDV6 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, PIK3CB, ZNF211, ZNF85, ZNF189, ZNF212 | More | | Verapamil | hsa05170 | Human immunodeficiency virus 1 infection | 7.66E-03 | 10 | P42338, P62873, P50151, P0DP23, P17252, P30101, P01568, P25963, P19174, P23528 | PIK3CB, GNB1, GNG10, CALM1, PRKCA, PDIA3, IFNA21, NFKBIA, PLCG1, CFL1 | More | | Verapamil | hsa05171 | Coronavirus disease - COVID-19 | 6.57E-03 | 14 | P01584, P25963, P42224, P01568, P62753, P25398, P36578, P32969, P18077, P62829, P40189, P42338, P19174, P17252 | IL1B, NFKBIA, STAT1, IFNA21, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23, IL6ST, PIK3CB, PLCG1, PRKCA | More | | Verapamil | hsa05200 | Pathways in cancer | 9.80E-05 | 21 | Q13751, P42338, P08238, P42224, P25963, P19174, P17252, P43246, P10826, P14923, Q13489, P49767, P14921, P62873, P50151, P78417, O75293, P0DP23, P01568, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, RARB, JUP, BIRC3, VEGFC, ETS1, GNB1, GNG10, GSTO1, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | | Verapamil | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | Verapamil | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Verapamil | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Verapamil | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Verapamil | hsa05214 | Glioma | 2.73E-03 | 5 | P0DP23, P17252, P42338, P19174, O75293 | CALM1, PRKCA, PIK3CB, PLCG1, GADD45B | More | | Verapamil | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | Verapamil | hsa05222 | Small cell lung cancer | 1.10E-02 | 6 | P10826, P42338, Q13751, Q13489, P25963, O75293 | RARB, PIK3CB, LAMB3, BIRC3, NFKBIA, GADD45B | More | | Verapamil | hsa05223 | Non-small cell lung cancer | 4.91E-03 | 5 | P17252, P42338, P19174, P10826, O75293 | PRKCA, PIK3CB, PLCG1, RARB, GADD45B | More | | Verapamil | hsa05225 | Hepatocellular carcinoma | 1.85E-02 | 2 | Q92529, P51531 | SHC3, SMARCA2 | More | | Verapamil | hsa05231 | Choline metabolism in cancer | 1.66E-04 | 9 | Q02750, P42338, P09619, Q9GZP0, O15245, Q9Y259, P19174, P23743, P17252 | MAP2K1, PIK3CB, PDGFRB, PDGFD, SLC22A1, CHKB, PLCG1, DGKA, PRKCA | More | | Verapamil | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Verapamil | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Verapamil | hsa05332 | Graft-versus-host disease | 8.79E-03 | 3 | P01375, P26715, Q13241 | TNF, KLRC1, KLRD1 | More | | Verapamil | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | Verapamil | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | Verapamil | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | | Verapamil | hsa05418 | Fluid shear stress and atherosclerosis | 2.43E-03 | 7 | Q16539, P42338, P10599, P14780, P01375, P14778, P27930 | MAPK14, PIK3CB, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |